Angela Boland

4.8k total citations · 2 hit papers
118 papers, 3.4k citations indexed

About

Angela Boland is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Economics and Econometrics. According to data from OpenAlex, Angela Boland has authored 118 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Pulmonary and Respiratory Medicine, 31 papers in Oncology and 19 papers in Economics and Econometrics. Recurrent topics in Angela Boland's work include Lung Cancer Treatments and Mutations (20 papers), Health Systems, Economic Evaluations, Quality of Life (15 papers) and Lung Cancer Diagnosis and Treatment (15 papers). Angela Boland is often cited by papers focused on Lung Cancer Treatments and Mutations (20 papers), Health Systems, Economic Evaluations, Quality of Life (15 papers) and Lung Cancer Diagnosis and Treatment (15 papers). Angela Boland collaborates with scholars based in United Kingdom, United States and Spain. Angela Boland's co-authors include Rumona Dickson, Y Dündar, A Bagust, Mary Gemma Cherry, J Greenhalgh, T Walley, C McLeod, Nigel Fleeman, J Oyee and Kerry Dwan and has published in prestigious journals such as The Lancet, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Angela Boland

112 papers receiving 3.3k citations

Hit Papers

Doing A Systematic Review: A Student’s Guide 2020 2026 2022 2024 2020 2022 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Doing A Systematic Review: A Student’s Guide
    2020 326 citations Angela Boland, Mary Gemma Cherry et al. profile →
  2. Association of Food and Nonalcoholic Beverage Marketing With Children and Adolescents’ Eating Behaviors and Health
    2022 107 citations Michelle Maden, Juliet Hounsome et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Angela Boland United Kingdom 37 798 600 397 372 306 118 3.4k
Michael Steinberg United States 33 877 1.1× 426 0.7× 623 1.6× 182 0.5× 448 1.5× 148 4.2k
Juliet A. Usher‐Smith United Kingdom 30 503 0.6× 743 1.2× 471 1.2× 333 0.9× 444 1.5× 150 3.7k
Rumona Dickson United Kingdom 33 507 0.6× 328 0.5× 294 0.7× 339 0.9× 191 0.6× 111 3.3k
A Bagust United Kingdom 36 535 0.7× 491 0.8× 256 0.6× 939 2.5× 332 1.1× 97 3.6k
Jonathan D. Campbell United States 32 940 1.2× 402 0.7× 300 0.8× 600 1.6× 208 0.7× 121 4.1k
Piet Bakker Netherlands 32 374 0.5× 743 1.2× 701 1.8× 250 0.7× 559 1.8× 104 3.7k
Mona Jeffreys United Kingdom 31 496 0.6× 1.1k 1.9× 554 1.4× 223 0.6× 281 0.9× 104 3.2k
David Lawrence United States 25 1.3k 1.7× 272 0.5× 282 0.7× 234 0.6× 553 1.8× 87 3.4k
Bruce Fireman United States 26 442 0.6× 820 1.4× 297 0.7× 659 1.8× 211 0.7× 41 3.3k
Hyeon Woo Yim South Korea 36 306 0.4× 439 0.7× 460 1.2× 164 0.4× 430 1.4× 244 5.4k

Countries citing papers authored by Angela Boland

Since Specialization
Citations

This map shows the geographic impact of Angela Boland's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Angela Boland with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Angela Boland more than expected).

Fields of papers citing papers by Angela Boland

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Angela Boland. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Angela Boland. The network helps show where Angela Boland may publish in the future.

Co-authorship network of co-authors of Angela Boland

This figure shows the co-authorship network connecting the top 25 collaborators of Angela Boland. A scholar is included among the top collaborators of Angela Boland based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Angela Boland. Angela Boland is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Taylor, Christopher D. J., Rebecca Coleman, Chris Sutton, et al.. (2025). iMAgery Focused Therapy for PSychosis (iMAPS-2): An Assessor-blind Feasibility Randomized Controlled Clinical Trial. Schizophrenia Bulletin. 51(Supplement_3). S317–S335.
2.
Fleeman, Nigel, Rachel Houten, Sarah J Nevitt, et al.. (2024). Lenvatinib plus pembrolizumab for untreated advanced renal cell carcinoma: a systematic review and cost-effectiveness analysis. Health Technology Assessment. 28(49). 1–190.
3.
4.
Bresnahan, Rebecca, Rachel Houten, J Greenhalgh, et al.. (2023). Pegcetacoplan for Treating Paroxysmal Nocturnal Haemoglobinuria: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics - Open. 7(4). 525–536.
5.
Chaplin, Marty, Rebecca Bresnahan, Nigel Fleeman, et al.. (2023). Onasemnogene Abeparvovec for Treating Pre-symptomatic Spinal Muscular Atrophy: An External Assessment Group Perspective of the Partial Review of NICE Highly Specialised Technology Evaluation 15. PharmacoEconomics - Open. 7(6). 863–875. 6 indexed citations
6.
Bresnahan, Rebecca, Rui Duarte, James Mahon, et al.. (2023). Diagnostic accuracy and clinical impact of MRI-based technologies for patients with non-alcoholic fatty liver disease: systematic review and economic evaluation. Health Technology Assessment. 27(10). 1–115. 4 indexed citations
7.
Fleeman, Nigel, Rachel Houten, A Bagust, et al.. (2020). Lenvatinib and sorafenib for differentiated thyroid cancer after radioactive iodine: a systematic review and economic evaluation. Health Technology Assessment. 24(2). 1–180. 30 indexed citations
8.
Hounsome, Juliet, Gerlinde Pilkington, James Mahon, et al.. (2020). Prophylactic removal of impacted mandibular third molars: a systematic review and economic evaluation. Health Technology Assessment. 24(30). 1–116. 33 indexed citations
9.
Fleeman, Nigel, Rachel Houten, Marty Chaplin, et al.. (2019). A systematic review of lenvatinib and sorafenib for treating progressive, locally advanced or metastatic, differentiated thyroid cancer after treatment with radioactive iodine. BMC Cancer. 19(1). 1209–1209. 34 indexed citations
10.
Duarte, Rui, Angela Stainthorpe, J Greenhalgh, et al.. (2019). The clinical and cost effectiveness of lead-I electrocardiogram (ECG) devices for detecting atrial fibrillation using single-time point testing in primary care: a systematic review and economic evaluation. Health Technology Assessment. 1 indexed citations
11.
Greenhalgh, J, A Bagust, Angela Boland, et al.. (2013). Rituximab for the First-Line Maintenance Treatment of Follicular Non-Hodgkin’s Lymphoma. PharmacoEconomics. 31(5). 403–413. 24 indexed citations
12.
Cherry, Mary Gemma, J Greenhalgh, Leeza Osipenko, et al.. (2012). The clinical effectiveness and cost-effectiveness of primary stroke prevention in children with sickle cell disease: a systematic review and economic evaluation.. Health Technology Assessment. 16(43). 1–129. 34 indexed citations
13.
Hockenhull, Jo, Mary Gemma Cherry, James Mahon, et al.. (2012). A systematic review of the clinical effectiveness and cost-effectiveness of Pharmalgen® for the treatment of bee and wasp venom allergy.. Health Technology Assessment. 16(12). III–IV, 1. 54 indexed citations
14.
Greenhalgh, J, A Bagust, Angela Boland, et al.. (2011). Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis. Health Technology Assessment. 15(31). 1–178. 25 indexed citations
15.
Fleeman, Nigel, C Martin Saborido, Katherine Payne, et al.. (2011). The clinical effectiveness and cost-effectiveness of genotyping for CYP2D6 for the management of women with breast cancer treated with tamoxifen: a systematic review.. Health Technology Assessment. 15(33). 1–102. 41 indexed citations
16.
Kaltenthaler, Eva, Angela Boland, Christopher Carroll, et al.. (2011). Evidence review group approaches to the critical appraisal of manufacturer submissions for the NICE STA process: a mapping study and thematic analysis. Health Technology Assessment. 15(22). 1–82, iii. 15 indexed citations
17.
18.
Hockenhull, Juliet, Kerry Dwan, G Smith, et al.. (2009). The clinical effectiveness of central venous catheters treated with anti-infective agents in preventing catheter-related bloodstream infections: A systematic review*. Critical Care Medicine. 37(2). 702–712. 68 indexed citations
19.
20.
Black, Corri, A Bagust, Angela Boland, et al.. (2006). The clinical effectiveness and cost-effectiveness of computed tomography screening for lung cancer: systematic reviews. Health Technology Assessment. 10(3). iii–iv, ix. 46 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michael Steinberg Breakdown of academic impact, for papers by Juliet A. Usher‐Smith Breakdown of academic impact, for papers by Rumona Dickson Breakdown of academic impact, for papers by A Bagust Breakdown of academic impact, for papers by Jonathan D. Campbell Breakdown of academic impact, for papers by Piet Bakker Breakdown of academic impact, for papers by Mona Jeffreys Breakdown of academic impact, for papers by David Lawrence Breakdown of academic impact, for papers by Bruce Fireman Breakdown of academic impact, for papers by Hyeon Woo Yim
Rankless by CCL
2026